• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » HRS 2019 Roundup: Medtronic touts extravascular ICD pilot

HRS 2019 Roundup: Medtronic touts extravascular ICD pilot

May 13, 2019 By Brad Perriello

Medtronic's extravascular ICDThe pilot study of an extravascular implantable cardiac defibrillator developed by Medtronic (NYSE:MDT), which is designed to deliver both defibrillation and anti-tachycardia pacing using leads placed outside the heart and venous system, showed strong safety and efficacy results.

The safety outcome for the 26-patient study, presented last week at the annual meeting of the Heart Rhythm Society in San Francisco, was the rate of freedom from major complications at three months. The efficacy measure was the inducement, detection and conversion of ventricular fibrillation episodes; patients were followed at two weeks, four to six weeks and three months after implantation.

Of the 21 patients implanted with the EV ICD device, defib testing was complete on 19, with successful inducement and termination in 17 or 89.5%, and a more than 95% rate of pacing capture. One episode of ventricular tachycardia outside the hospital was successfully detected and treated by the device, Medtronic said.

“The successful pilot study revealed valuable insights to inform our EV ICD clinical program and we are eager to incorporate the learnings from this study into a pivotal trial,” Cardiac Rhythm and Heart Failure CMO Dr. Rob Kowal said in prepared remarks. “Medtronic appreciates the contributions of the investigators and patients and we are proud to lead the way in ICD innovation for patients who need protection from life-threatening heart rhythms.”

“I am very encouraged by our pilot experience using the Medtronic EV ICD system in patients out to three months,” added principal investigator Dr. Ian Crozier of New Zealand’s Christchurch Hospital. “This small but important study affirms the potential of this new extravascular approach to provide pacing and lifesaving defibrillation therapy without the risks that accompany transvenous leads implanted inside the heart and veins.”

 Boston Scientific’s Emblem S-ICD fares well in primary prevention study
A 1,116-patient study of primary prevention using BSX’s Emblem S-ICD device in patients with left ventricular ejection fractions of 35% or less showed a 95.8% rate of freedom from complications, a 99.6% rate of successful implantation at 30 days and an 99.2% rate of successful defbrillator conversion.

“The data presented today reiterate the value of the Emblem S-ICD System for a broad group of ICD-indicated patients, enabling them to avoid the long-term complications associated with TV-ICD leads,” global health policy & rhythm management CMO Dr. Kenneth Stein said in prepared remarks. “We remain proud of the clinical success of the S-ICD System, which has now been implanted in nearly 60,000 patients worldwide, and we will continue to invest in clinical studies that advance our understanding of the role of the device in patients at risk of sudden cardiac death.”

“We found that the complication rate within this primary prevention population was as low as in prior S-ICD registries, despite the patients having much lower LVEF, more hypertension, and diabetes – underscoring that sicker patients do well with this device for the prevention of sudden death,” added principal investigator Dr. Lucas Boersma of Holland’s St. Antonius Hospital. “These acute outcomes also validate the advantages of the two-incision implant technique, which has continued to gain worldwide adoption in the last few years.”
Read more

 CardioFocus touts HeartLight X3 study
CardioFocus said a study of the latest iteration of its visualization and ablation catheter, the HeartLight X3, cut procedure times by mroe than 90 minutes and showed comparable safety and efficacu compared with the first-generation device.

“CardioFocus is experiencing tremendous growth; more than 6,500 patients have been treated with our revolutionary HeartLight system and the HeartLight X3 system is poised to make a real impact on the AFib ablation space with its recent CE Mark approval,” president & CEO Burke Barrett said in prepared remarks. “We believe coupling the HeartLight System’s unique feature set and its safety and effectiveness profile with the straightforward introduction of X3 Rapid mode for accelerating procedures, will result in an unparalleled PVI ablation tool.”

“Our trial results using the HeartLight X3 System were outstanding, with the study meeting all the pre-specified endpoints,” added lead investigator Dr. Petr Neužil of Prague’s Na Homolce Hospital. “With faster PVI and faster total ablation times combined with the already established safety and efficacy of the current HeartLight System, I anticipate that the HeartLight X3 System will be quickly adopted in the clinical setting.”
Read more

 Javelin Medical’s Vine embolic coil passes FIH feasiblity study
An embolic coil developed by Javelin Medical to reduce the risk of stroke in Afib patients who can’t take anti-coagulant drugs passed a first-in-human feasibility study.

The Vine device is designed to be placed transcutaneously into both common carotid arteries to trap debris that mioght travel downstream and cause a stroke. The 25-patient feasibility study had a safety endpoint of the rate of major adverese events and an efficacy endpoint of procedural success, both at 30 days.

The Capture study showed a 0% rate of major adverse events and a 20% rate of minor AEs, consisting of five cases of puncture site hematoma and/or edema. The procedural success rate was 92% at 30 days. After six months there was no evidence of in situ clot formation and the filter captured clots in four patients, which were dissolved with heparin. One patients suffered two minor strokes from clots outside the carotid arteries.

“These promising data should prompt large prospective randomized trials,” according to the study’s authors.
Read more

  • Promising one-year outcomes for AFTx’s real-time rotor mapping algorithm
  • MediLynx touts micro-AF monitoring as predictor
  • Preventice Solutions touts long-term cardiac monitoring with BodyGuardian device
  • J&J’s Biosense Webster launches Cartonet
  • Spacelabs debuts Sentinel 11 software
  • Medtronic: Studies show CRM devices are underused

Filed Under: Cardiovascular, Clinical Trials, Featured Tagged With: AFTx, Biosense Webster, Boston Scientific, Cardiac Rhythm Management, Cardiofocus, HRS 2019, Javelin Medical, Johnson and Johnson, MediLynx, Medtronic, Preventice, Spacelabs Healthcare

In case you missed it

  • They said it at DeviceTalks Boston
  • Elucid raises $27M for heart disease diagnosis software
  • Summer health technology program brings diverse group of interns to Silicon Valley
  • BioSig expects to raise $3.5M from public offering
  • Haemonetics completes move to new Pennsylvania manufacturing facility
  • Vivera adds two industry veterans to its technology advisory board
  • Abbott Fund grants $750k to education, health equity program
  • Another Medtronic HVAD recall is serious
  • Endologix reports positive results from percutaneous bypass trial
  • NorthStar Medical names new president and chief operating officer
  • Vektor Medical names Rob Krummen as CEO
  • Baxter’s Volara lung therapy system recall is Class I
  • BD voluntarily recalls intraosseous products
  • Bioventus restructures $315M CartiHeal acquisition
  • Intrommune extends scope of Phase 1 trial for peanut-allergy-treating toothpaste
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
  • Hamilton Medical warns on some ventilators

RSS From Medical Design & Outsourcing

  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]
  • Clippard releases new series of isolation valves
    Clippard (Cincinnati) has Its Clippard NIV Series media isolation valve — a solenoid-operated device using a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves find everyday use in a wide variety of applications. Think uses that require precise, repeatable dispensing of media for analytical instrumentation. Clippard says media isolation… […]
  • Another Medtronic HVAD recall is serious
    A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this… […]
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
    SeaStar Medical recently won FDA breakthrough device designation for a new way to treat hyperinflammation with technology that could help fight chronic conditions from COVID-19 infections. The Denver-based medical developer is seeking a humanitarian device exemption for treating children with acute kidney injury (AKI) based on an FDA-funded study, SeaStar President and CEO Eric Schlorff… […]
  • How Avail Medsystems seeks to create a connected OR experience
    Much like a normal Starbucks-goer expects the coffee to taste a certain way at any location, Daniel Hawkins wants that type of experience in the operating room. Hawkins is the CEO of Avail Medsystems, a company developing telemedicine equipment that can connect surgeons, interventional specialists and medical device sales reps. Hawkins and the team at Avail… […]
  • How to leverage technology to drive diversity in clinical studies
    Convenience was the driver, and the traditional clinical trial model had to evolve when it came to a colorectal cancer screening study. The clinical study had 35,000 patients across the U.S. Chuanbo Xu, Freenome Cancer doesn’t discriminate. It’s the second-leading cause of death in the U.S. Early detection is key in treating — and even… […]
  • Medical device licensing pitfalls to avoid
    Prevent costly disputes caused by these common mistakes in patent license agreements. Marcelo Barros, Kathleen Daley, Brian Kacedon and Matthew Ritter, Finnegan Licensing and other technology transfer agreements can be critical for medical device companies that invest significantly into new technology R&D and seek and obtain intellectual property protection for those investments. But if these agreements… […]
  • Tolerance stack-up: Insight into the inner workings of high-density microelectronic medical devices
    Tolerance stack-up is a defining design concept to ensure new products are built efficiently and effectively.  Darren Gilmer, Intricon At a time when the future of micro-miniature medical devices seems unlimited, one fundamental reality remains firmly in place — the sizes and shapes of human anatomy. From blood vessels to ear canals, respiratory passages to… […]
  • Deburring and finishing for beautiful, functional medical devices
    The latest automated cutting tools help medical device manufacturers meet strict specs and high demand. Dave Sawicki, Xebec Increasing demand and advances in technology are driving growth in the medical device industry. Chronic diseases are more prevalent, and the aging population is larger, contributing to the demand for highly regulated Class III medical devices such… […]
  • FDA seeking innovations to move beyond heater-cooler device problems
    The FDA issued a notice today saying that it is working to evaluate new strategies to mitigate infections associated with heater-cooler devices. According to the notice, the administration is collaborating with professional societies, public health partners, heater-cooler manufacturers, and experts on the matter surrounding the heater-cooler devices used during medical and surgical procedures to warm… […]

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS